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Abstract 31 
One of the current strategies to prevent malaria in pregnancy is intermittent preventive treatment 32 
with sulfadoxine-pyrimethamine (IPTp-SP). However, in order for pregnant women to receive an 33 
adequate number of SP doses, they should attend a health facility on a regular basis. In addition, SP 34 
resistance may decrease IPTp-SP efficacy. New or additional interventions for preventing malaria 35 
during pregnancy are therefore warranted. Because it is known that community health workers 36 
(CHW) can diagnose and treat malaria in children, in this study screening and treatment of malaria in 37 
pregnancy by CHWs was evaluated as an addition to the regular IPTp-SP program. CHWs used rapid 38 
diagnostic tests (RDT) for screening and artemether-lumefantrine was given in case of a positive 39 
RDT. Overall, CHWs were able to conduct RDTs with a sensitivity of 81.5% (95%CI 67.9 – 90.2) and 40 
high specificity of 92.1% (95%CI 89.9 – 93.9) compared with microscopy. After a positive RDT, 79.1% 41 
of women received artemether-lumefantrine. When treatment was not given, this was largely due to 42 
the woman being already under treatment. Almost all treated women finished the full course of 43 
artemether-lumefantrine (96.4%). In conclusion, CHWs are capable of performing RDTs with high 44 
specificity and acceptable sensitivity, the latter being dependent on the limit of detection of RDTs. 45 
Furthermore, CHWs showed excellent adherence to test results and treatment guidelines, 46 
suggesting they can be deployed for screen and treat approaches of malaria in pregnancy. 47 
 48 
 49 
50 
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 51 
Background 52 
Malaria in pregnancy can cause several adverse outcomes such as maternal anemia, 53 
stillbirths, miscarriage and low birth weight (reviewed by Desai et al.).1 The current key strategy for 54 
prevention of malaria in pregnancy is intermittent preventive treatment with sulfadoxine-55 
pyrimethamine (IPTp-SP). IPTp-SP consists in the administration of SP during the second and third 56 
trimester when the women attend the antenatal care clinic (ANC),2 and has proven effective in 57 
preventing placental malaria and low birth weight.3 The WHO recommends that SP is administered 58 
at each antenatal care visit in the second and third trimester, provided it is at least a month apart 59 
from the previous dose.2 However, IPTp-SP coverage of at least two doses is low in many Sub-Sahara 60 
African countries (on average 21.5%).4 Reasons for low coverage are a lack of coordination and 61 
leadership, financial constraints, unmotivated and unsupported health staff, perceived risk of the 62 
medication, logistic challenges and ANC attendance among others.5–7 Adolescents and 63 
primigravidae, who have among pregnant women the highest risk of malaria, are even less likely to 64 
receive sufficient doses of IPTp-SP, mainly due to low ANC attendance.6 Besides the unsatisfactory 65 
uptake of IPTp-SP, SP resistance is widespread and rising in most sub-Saharan African countries.8–10 66 
In East Africa, where resistance is the highest of sub-Saharan Africa,11 the efficacy of IPTp-SP seems 67 
already compromised.12–15 Therefore, it is important to explore alternative or additional preventive 68 
measures.  69 
Community case management of malaria (CCMm) aims at reducing malaria morbidity in 70 
children, by improving the access to diagnosis and treatment of malaria. CCMm relies on members 71 
of community, often named community health workers (CHW), who have been trained in diagnosing 72 
malaria with rapid diagnostic tests (RDTs) and administering an antimalarial treatment to positive 73 
tested children.16 The strategy is effective as CHWs are capable of performing RDTs with a fair 74 
sensitivity (generally over 85% compared with microscopy).17 Because of these positive results, an 75 
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intervention based on this strategy was considered for pregnant women. In this intervention CHWs 76 
were mobilized to screen pregnant women for malaria with RDTs at monthly intervals, between 77 
antenatal care visits.18 Besides increasing the chance of detecting and treating malaria infections, 78 
this strategy also increases the total number of health-care contacts during pregnancy, something 79 
that is strongly encouraged by the WHO.19 The performance of RDTs used by CHWs on pregnant 80 
women in rural Burkina Faso is reported here, including the adherence of CHWs and pregnant 81 
women to the test results and to treatment guidelines.  82 
 83 
Methods 84 
This study was nested in a cluster-randomized controlled trial (COSMIC; Trial Registration: 85 
Current Controlled Trials ISRCTN37259296 and clinicaltrials.gov NCT01941564) carried out in Benin, 86 
The Gambia and Burkina Faso, as described previously.18 The aim of the main trial was to assess the 87 
efficacy of community screening and treatment of malaria during pregnancy on placental malaria. 88 
Here, the quality of RDT use by CHWs in pregnant women and adherence to treatment guidelines is 89 
described for the Burkina Faso study site.  90 
 91 
Study procedures 92 
The intervention of community screening and treatment of malaria during pregnancy was 93 
conducted in 15 villages in the Nanoro health centre catchment area, about 85 km North-West of 94 
Ouagadougou. Malaria is endemic in this region, but has a seasonal pattern with peak transmission 95 
occurring towards the end of the rainy season (that lasts from June until October). CHWs were 96 
instructed to pay monthly visits to pregnant women in their second and third trimester up to 97 
delivery. In each village there was a single CHW participating in the study, except for one village in 98 
which the initial CHW got a new job outside the study area and was therefore replaced. At each 99 
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home visit, CHWs performed a RDT (SD Bioline Ag-Pf), irrespective of symptoms, and if positive 100 
administered artemether-lumefantrine (COARTEM®). Treatment was not given if a woman reported 101 
to have received a course of artemether-lumefantrine in the past three weeks. Seriously ill women 102 
were referred to the health center. RDT results and any given treatment were recorded on a CRF by 103 
the CHW (supplemental file 1). In addition, the CHW collected a blood slide and blood spots on filter 104 
paper. All treated women were visited after three days by the CHW, to assess treatment adherence 105 
by administering a questionnaire and by checking the empty blisters. The number of tablets 106 
remaining and reasons for non-adherence were recorded in another CRF (supplemental file 2). 107 
Besides the home visits, pregnant women were encouraged by the CHWs to visit the ANC. At each 108 
ANC visit the woman received standard care, including IPTp-SP. Furthermore, a blood slide and filter 109 
paper were collected and clinical data and any given treatment was recorded on a CRF 110 
(supplemental files 3 and 4).  111 
 112 
Study population and sample size 113 
All women resident in the study area and without a known sensitivity to sulphonamides 114 
were eligible for inclusion in the COSMIC study. Pregnant women enrolled in intervention villages (n 115 
= 900) in Burkina Faso were included in the analyses of the current study.18  116 
 117 
Community health workers 118 
CHWs included in the study were already involved in community sensitization and 119 
organization of vaccination and malnutrition campaigns. Each of the CHWs was linked to a health 120 
facility. CHWs followed a program before the beginning of the trial in which they were trained in 121 
malaria symptoms and recognition of danger signs, the use of RDTs and the need and purpose of 122 
screening pregnant women for malaria. They were also explained the benefits of IPTp-SP and 123 
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advised to promote ANC visits and SP uptake among the pregnant women. CHWs were supervised 124 
by field workers. 125 
 126 
Rapid diagnostic tests 127 
RDTs used by the CHWs targeted the P. falciparum histidine-rich protein 2 (HRP2) antigen. A 128 
central stock of RDTs was kept at the Unité de Recherche Clinique de Nanoro (URCN) and the CHWs 129 
were supplied with small stocks at a regular basis. In case of an invalid test result, CHWs were 130 
instructed to repeat the RDT.  131 
 132 
Microscopy 133 
Filter papers and blood slides collected at home visits in intervention villages were 134 
transferred to the laboratory (URCN) on the same day. Blood slides were stained with Giemsa 3% for 135 
45 – 60 minutes. Slides were read by two independent expert microscopists blinded to the RDT 136 
results. The number of parasites were counted against 200 leukocytes, or against 500 leukocytes if 137 
the count was <10 parasites/200 leukocytes. Slides were considered negative if no parasites were 138 
seen after examination of 100 high power fields. Any discrepancies between the two readings were 139 
resolved by consulting a third independent blinded reader.  140 
 141 
Real-time PCR  142 
Filter papers were air dried, sealed in bags with silica and stored at room temperature until 143 
shipment to the Netherlands (Academic Medical Centre, Amsterdam). For each selected filter paper 144 
a blood spot was punched out using acu-punch skin biopsy punchers (acuderm® inc, Florida, USA) 145 
and transferred to a 5 mL polystyrene tube with lysis buffer (bioMérieux, Marcy-l’Étoile, France). The 146 
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tubes were placed on a roller bank for 30 minutes. After lysis, the fluid was transferred to EasyMAG 147 
vessels and Magnetic Bead Silica were added. DNA was extracted using the NucliSENS EasyMAG DBS 148 
1.0 protocol (bioMérieux, Marcy-l’Étoile, France). Positive and negative controls were included 149 
(blood spots from EDTA blood spiked with 3D7 or FCR3 culture and blood spots of uninfected EDTA 150 
blood of the Dutch blood bank). Samples were stored at -20 ˚C.  151 
Real-time PCR for detection of Plasmodium falciparum DNA was performed as previously 152 
described with minor modifications.20,21 In each reaction 2.5 µl of DNA, 5 mM MgCl2, 2.5 µl of 10x 153 
PCR Buffer, 0.125 µl of HotStarTaq DNA Polymerase, 0.25 mM of each dNTP, 0.4 µM of each primer 154 
and 0.1 µM of FAM-labelled probe (‘5-aacaattggagggcaagg-3’) was used. PCR Mix reagents were 155 
ordered from Qiagen (Hilden, Germany)  and all primers from Biolegio (Nijmegen, the Netherlands). 156 
In each plate a dilution series of P. falciparum FCR3 culture was included (104 parasites/µL – 1 157 
parasites/µL) as well as positive and negative DNA extraction controls and Milli-Q water. Reactions 158 
were run on BioRad CFX real-time PCR machine with the following settings: initial denaturation 95°C 159 
for 10 minutes, 40 cycles of 95°C for 60 seconds and 60°C for 20 seconds. Results were analyzed 160 
using Bio-Rad CFX manager software (version 3.1). 161 
 162 
Statistical analyses 163 
All analyses were done using Stata 14.0. Microscopy was used as the reference test for RDT 164 
performance. A sub-analysis at first home visit was done with real-time PCR as the reference test, 165 
because it has been shown that sub-microscopic infections are also clinically important as they can 166 
result in maternal anemia and preterm or low birth weight babies.22 Sensitivity (proportion of 167 
correctly identified positive samples), specificity (proportion of correctly identified negative 168 
samples), positive predictive value (proportion of diseased after a positive RDT result; PPV), negative 169 
predictive values (proportion of non-diseased after a negative RDT result; NPV) and prevalence 170 
(proportion of positive test results of all tests performed) were calculated by using logistic regression 171 
9 
 
with robust standard errors to take clustering of tests within CHWs into account. For sensitivity and 172 
specificity analysis stratified by CHW, logistic regression with robust standard errors was used to 173 
account for repeated measurements of participants. However, for CHWs with 100% RDT sensitivity 174 
exact binomial confidence intervals were calculated since no between woman variation was 175 
observed. For comparisons of parasite density, Mann-Whitney U tests were performed for skewed 176 
data distributions.   177 
 178 
Ethics 179 
Informed consent was obtained for each participating community prior to the start of the 180 
trial. During the study informed consent was obtained for each participating woman. The study 181 
protocol was reviewed and ethically approved by the Institutional Ethics Committee of Centre Muraz 182 
in Burkina Faso on 19 September 2013 (ref A20-2013/CE-CM).  183 
 184 
Results 185 
Pregnant women were enrolled over a time period of 18 months; including follow-up the 186 
study lasted approximately 2 years in Burkina Faso (March 2014 – January 2016). A total of 900 187 
women were recruited in 15 villages allocated to the intervention arm; of 861 women at least one 188 
home visit was recorded (Figure 1). The mean age of the women was 26 years olds (SD 6.3), with 189 
10.5% of the women aged 18 or below. 19.2% (165/861) of women were primigravidae and 14.9% 190 
(128/861) secundigravidae. The modal number of visits per pregnancy was 3 (40.0%) though some 191 
women had up to 6 visits (Table 1). In total, 2516 home visits were done. There were 2,507 recorded 192 
RDT results, with 307 (12.2%) positive tests; 242 women tested positive at least once (up to a 193 
maximum of 4 times) (Figure 1). Of all microscopy slides, 147 of 2443 (6.0%) were positive. Over 194 
subsequent home visits, the proportion of positive RDTs was consistently higher than that of positive 195 
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microscopy (p values 0.011; <0.001; <0.001; 0.003; 0.017 for home visits 1 to 5 respectively) (Figure 196 
2).  197 
 198 
RDT versus microscopy 199 
Using microscopy as the reference test, RDT sensitivity was 81.5% (95%CI 67.9 – 90.2) and 200 
specificity 92.1% (95%CI 89.9 – 93.9); positive predictive value (PPV) was 39.8% (95%CI 33.0 – 47.0) 201 
and negative predictive value (NPV) was 98.7% (95%CI 97.6 – 99.3) (Table 2). When stratified by 202 
home visit (Table 3), sensitivity ranged between 74.1 and 87.0% without a clear trend over 203 
successive home visits (p = 0.115). However, specificity decreased over successive home visits (point 204 
estimates decreased from 96.4 to 87.4%, p < 0.001). Consequently, the PPV differed significantly 205 
between home visits (p < 0.001); a decrease in PPV was seen over successive home visits, except at 206 
home visit 4 due to higher malaria prevalence by microscopy. The NPV remained high over 207 
successive home visits without significant differences (p = 0.086) 208 
Individual differences between CHWs in RDT sensitivity and specificity are presented in 209 
Figures 3a and b. Sensitivity ranged from 27.3 up to 100% and specificity from 84.6 to 98.3%. 210 
Variance between CHWs was significant for both sensitivity and specificity with intracluster 211 
coefficients of 0.37 (p < 0.001) and 0.05 (p < 0.001) respectively. In particular, two CHWs (numbers 212 
12 and 14) showed poor sensitivity (50.0%, 95%CI 15.8 – 84.2 and 27.3%, 95%CI 8.1 – 61.4 213 
respectively). Due to the low overall prevalence the NPV remained high, 95.6% (95%CI 89.1 – 98.3) 214 
and 93.2% (95%CI 86.3 – 96.7) for CHW 12 and 14 respectively. If the two CHWs were excluded from 215 
the analyses, the overall sensitivity increased to 88.2% (95%CI 79.8 – 93.4) while the specificity 216 
remained similar.   217 
Discrepancies between RDT and microscopy results were further explored (Tables 4 and 5). 218 
Parasite densities in microscopy positive slides (reference test) were compared between positive 219 
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(true positives) and negative RDTs (false negatives); for the former, the median parasite density was 220 
2019.3 parasites/ L (IQR 703.5 – 4994.0) while it was 104 parasites/ L (IQR 72.0 – 530.5) for the 221 
latter (p < 0.001) (Table 4). Almost half of the women (48.9%, 88/180) with RDT positive and 222 
microscopy negative results (false positives) had taken anti-malarial treatment (AL, SP or quinine) 223 
within the two weeks before the RDT testing was performed; this was 62.6% (113/180) when 224 
considering the previous four weeks. When including reported but unproven treatment, the 225 
proportions increased to 56.1% (101/180) and 72.8% (131/180) respectively (Table 5).  226 
 227 
RDT versus real-time PCR 228 
From first home visit, 628 RDTs were available for analyses. Malaria prevalence by real-time 229 
PCR was 6.0% (95% CI 4.3-8.1%). When taking real-time PCR as reference test and after correction 230 
for clustering, RDT sensitivity was 75.7% (95% CI 66.2 – 83.2) and specificity 96.6% (95%CI 94.2 – 231 
98.0) (Table 3). 232 
Median parasite density (by real-time PCR) was 34.65 parasites/ L (IQR 10.4 – 111.3) in true 233 
positive RDTs and 1.12 parasites/ L (IQR 0.5 – 20.6) in false negative RDTs (p = 0.04) (Table 6). Of 234 
women with a false positive RDT, 40% (8/20) had used anti-malarial treatment within the last four 235 
weeks, when including reported but unproven treatment this increased to 55% (11/20) (Table 7).  236 
 237 
Adherence to test results by CHWs and pregnant women 238 
Of RDT positive women 79.1% (239/302) were treated with artemether-lumefantrine by the 239 
CHW. The most common reason for not giving treatment despite a positive RDT was ongoing 240 
treatment (77.9%). Furthermore, in 4 cases the CHW reported that he/she had no artemether-241 
lumefantrine in stock. For the remaining 11 cases, the reason for non-adherence to the treatment 242 
protocol is unknown (Table 8). Full adherence to the drug regimen by pregnant women was 96.5% 243 
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(no anti-malaria tablets left after three days). Reasons for non-adherence were side-effects (3/7), 244 
the woman forgot to take the medication (1/7) or the woman was already under treatment (1/7) 245 
(Table 8).  246 
 247 
Discussion 248 
CHW are able to screen pregnant women for malaria with RDTs and treat them adequately if 249 
positive. CHWs were able of performing RDTs with a fair sensitivity of 81.5% (95%CI 67.9 – 90.2) and 250 
specificity of 92.1% (95%CI 89.9 – 93.9). Previous studies on HRP2-based RDTs performed by 251 
professional health care showed higher sensitivity (94%, 95%CI 91 - 96) on average, but lower 252 
specificity (81%, 95%CI 71 – 88) in pregnant women (reviewed in Kattenberg et al.).23 These 253 
differences can be related to RDT brands used, endemic settings, or skills in execution of RDTs. The 254 
latter could also be the cause of CHWs not doing equally well in terms of RDT sensitivity in this study, 255 
with 2 CHWs (12 and 14) performing unsatisfactorily (sensitivities of 50% and 27% respectively). 256 
However, the CHWs were supervised at a regular basis during the study and no failures in RDT 257 
execution were reported by the field supervisors. Therefore, it remains unclear if this was a problem 258 
of RDT execution, or if there are other reasons. Previous studies have shown that mistakes in RDT 259 
execution are often related to the volume of blood and buffer used, the timing of reading, and/or 260 
incorrect interpretation of faint bands or invalid results.17  261 
False negative RDT results may be explained by the detection threshold of the test (around 262 
200 parasites/µL),24,25 as almost 60% of all false negatives had a lower density. The large majority 263 
(8/11) of RDT false negatives above the 200 parasites/ µL threshold, were missed by the two poorer 264 
performing CHWs, again suggesting mistakes in the execution of the tests. However, even if only 265 
well performing CHWs would screen pregnant women for malaria, it means that some women with 266 
low parasite densities would be left untreated. This is unfortunate since it has been shown that 267 
infections with low parasite densities are also related to maternal anemia, low birth weight and 268 
13 
 
premature births.22 Furthermore, the sensitivity of RDTs was calculated against microscopy of 269 
peripheral blood, while both these methods (as well as real-time PCR of peripheral blood) may miss 270 
placental infections.23 Therefore, the number of women with a malaria infection but not identified 271 
by a RDT is likely higher than presented here.  272 
Most false positive RDT results can probably be attributed to prolonged antigen circulation 273 
after clearance of a P. falciparum infection. While microscopy detects live parasites that are usually 274 
cleared within a few days after treatment, it has been shown that HRP2 antigens can persist in the 275 
circulation for at least 4 weeks after treatment in pregnant women.20 This explains the decreasing 276 
specificity over successive home visits; it reflects the increased chance of women having experienced 277 
a malaria infection from which HRP2 antigens are still circulating. In our study, 72.6% of the women 278 
had used or reported use of anti-malarial treatment in the 28 days preceding a false positive RDT. 279 
For the remaining false positive results, it could be that reporting anti-malarial treatment was not 280 
always accurate, resulting in a recall bias. It could also be that some false positive results were 281 
actually true positives, but missed by microscopy reading. This seems to be the case for some 282 
positive RDTs at home visit 1 that were tested negative by microscopy but positive by real-time PCR.   283 
The comparisons of RDT with real-time PCR resulted in a lower sensitivity 75.7 % (95% CI 284 
66.2 – 83.2) than with microscopy as reference test. Given that real-time PCR can detect even lower 285 
parasite densities than microscopy (~20 parasites/mL versus 50 – 100 parasites/µL respectively), this 286 
is to be expected.21,25 Compared with two other studies in Burkina Faso in which pregnant women 287 
were tested at antenatal care visits by professional health care workers, the sensitivity was high 288 
compared with one (sensitivity 55.8 %, 95%CI 50.0 – 62.4),26 but low compared with the other 289 
(90.9%, 95%CI 87.5, 93.6).27 However, both used a different test for comparison (nested PCR and not 290 
real-time PCR) which could impact on sensitivity; in addition, the latter study used both PCR and 291 
microscopy as reference test. The observation that parasite densities were significantly lower for 292 
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false negative RDT samples than for true positive RDT samples in our study, confirmed the idea that 293 
the major bottleneck was the detection limit of RDTs.  294 
The specificity of RDTs compared with real-time PCR was high (96.6%, 95%CI 94.2 – 98.0) 295 
and fairly similar to specificity found in the two previous studies in Burkina Faso (99.3%, 95%CI 98.4–296 
99.7 and 94.1%, 95%CI 89.4, 97.1).26,28 Antigen persistence of a cleared infection may again be the 297 
cause of the few false positive RDT results, because in contrast to antigen, DNA from dead 298 
Plasmodium parasites seems to be rapidly cleared from the bloodstream.29    299 
Adherence to test results by CHWs was excellent, given the fact that almost 80% of the 300 
women were treated after a positive RDT, and that the most common reason for not giving 301 
treatment was that the woman was already under treatment or had just finished treatment. This 302 
shows that CHWs were well trained in treatment guidelines and unlikely to over-treat the pregnant 303 
women. Good adherence to positive test results was shown in previous studies on CHWs.17 304 
Furthermore, the high adherence of pregnant women to the full course of AL shows the high trust in 305 
the CHWs and the test results, at least within this trial context.  306 
A limitation of this study was the quality of filter paper samples. While most CHWs seemed 307 
sufficiently trained in performing RDTs, the correct preparation of filter papers turned out to be 308 
more difficult. For most blood spots the amount of blood was less than the requested 50 µL for 309 
which the extraction and real-time PCR were validated. The lack of sufficient blood may have led to 310 
wrong estimations of parasite density and to false negative real-time PCR results if the parasite 311 
density was already low. However, because specificity was high for RDTs compared with real-time 312 
PCR as reference test, it is unlikely that the latter was an issue.  313 
Furthermore, it is unclear whether the screen and treat intervention by CHWs would work as 314 
well if it was implemented in the regular health care system, as the current results were obtained 315 
during a trial setting in which stock supply was carefully managed and CHWs were in close contact 316 
with field supervisors. This is something that should be evaluated after implementation. This study 317 
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has highlighted the qualities and the issues of screening pregnant women with relatively simple 318 
diagnostics for malaria by CHWs. CHWs can perform RDTs with acceptable sensitivity and high 319 
specificity and have shown good adherence to treatment guidelines. The biggest area for 320 
improvement, before implementing this intervention, would be thorough examination of correct 321 
execution of RDTs by all CHWs. Due to the intrinsic limitations of the current RDTs, cases with low 322 
parasite densities will nevertheless be missed. A new simple diagnostic point-of-care test, that can 323 
detect lower parasite densities and that is preferably less sensitive to antigen persistence, could 324 
therefore further improve overall performance. In any case, this study has shown that CHWs can be 325 
trained and instructed for innovative purposes, which might present new opportunities for other 326 
public health issues.   327 
 328 
329 
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 330 
Table 1. Characteristics of pregnant women with at least one home visit 331 
Participant characteristics (n = 861)   
Age, mean±SD, (median, IQR) 26±6.3 (26, 21 - 30) 
Gravidity   
Primigravidae, % (nr) 19.2  (165) 
Secundigravidae, % (nr) 14.9  (128) 
Multigravidae, % (nr) 66.0  (568) 
Nr. of home visits per woman, % (nr)   
1 9.3  (80) 
2 22.8  (196) 
3 40.0  (344) 
4 22.9  (197) 
5 4.6  (40) 
6 0.5  (4) 
 332 
 333 
334 
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 335 
Table 2. RDT performance compared with microscopy; sensitivity, specificity, PPV and NPV 336 
 337 
 338 
 339 
 340 
 341 
342 
RDT versus microscopy (n = 2434) Microscopy positive Microscopy negative Total 
RDT positive 119 180 299 
RDT negative 27 2108 2135 
Total  146 2288  
Sensitivity % (95% CI) 81.5 (67.9 – 90.2)   
Specificity % (95% CI) 92.1 (89.9 – 93.9)   
Positive predictive value % (95% CI) 39.8 (33.0 – 47.0)   
Negative predictive value % (95% CI) 98.7 (97.6 – 99.3)   
18 
 
 343 
Table 3. RDT sensitivity and specificity compared with microscopy and real-time PCR, stratified for 344 
home visits 1 - 4 345 
 346 
Home visit 5 and 6 not presented because of small sample sizes (n = 39 and n = 4 respectively) 347 
 348 
 349 
 Home visit 1 Home visit 2 Home visit 3 Home visit 4 p value 
RDT versus microscopy, n 837 759 567 228  
Sensitivity (95% CI) 78.6 (62.6 – 88.9) 87.0 (71.9 – 94.6) 74.1 (48.1 – 89.8) 82.8 (55.3 – 94.9) 0.115 
Specificity (95% CI) 96.4 (94.4 – 97.7) 90.3 (86.9 – 92.9) 91.1 (87.8 – 93.6) 87.4 (80.6 – 92.1) 0.000 
Positive predictive value % (95% CI) 53.2 (39.2 – 66.7) 36.7 (28.0 – 46.3) 29.4 (20.4 – 40.3) 49.0 (34.2 – 64.0) 0.000 
Negative predictive value % (95% CI) 98.8 (97.7 – 99.4) 99.0 (97.9 – 99.6) 98.6 (96.5 – 99.5) 97.2 (91.3 – 99.1) 0.086 
RDT versus qPCR, n 621 NA NA NA  
Sensitivity (95% CI) 75.7 (66.2 – 83.2) NA NA NA NA 
Specificity (95% CI) 96.6 (94.2 – 98.0) NA NA NA NA 
Positive predictive value % (95% CI) 58.3 (42.3 – 72.8) NA NA NA NA 
Negative predictive value % (95% CI) 98.4 (97.5 – 99.0) NA NA NA NA 
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Table 4. False negative RDT results (microscopy as reference test): real-time PCR results and parasite density  
 
 
 
 
Table 5. False positive RDT results (microscopy as reference test): real-time PCR results and recent anti-malarial treatment  
 
Discrepancy N PCR positive Parasite density* 
False negative RDT 
 (ref microscopy) 
27 (1.1%) 2/6 (33.3%) 16 had parasite density <200 p/µL (59.3%) 
Median: 104, IQR: 72 – 530.5 p/µL 
*by microscopy    
Discrepancy n PCR positive (HV1) AL treatment IPTp-SP Any treatment 
False positive RDT 
 (ref microscopy) 
180 (7.4%) 6/24 (25%) 50 had received AL in last 14 days (27.8%) 
72 had received AL in last 28 days (40.0%) 
47 reported being under treatment with AL 
 
49 had received SP in last 14 days (27.2%) 
64 had received SP in last 28 days (35.6%) 
 
88 had received AL, SP or quinine in last 14 days (48.9%) 
113 had received AL, SP or quinine in last 28 days (62.8%) 
101 reported or received AL, SP or quinine in last 14 days (56.1%) 
131 reported or received AL, SP or quinine in last 28 days (72.8%) 
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Table 6. False negative RDT results (real-time PCR as reference test):  microscopy results and parasite density  
 
 
 
 
Table 7. False positive RDT results (real-time PCR as reference test): microscopy results and recent anti-malarial treatment 
 
 
Table 8. Adherence to treatment guidelines after a positive RDT by CHWs and pregnant women 
Discrepancy n Microscopy positive Parasitemia* by qPCR 
False negative RDT 
 (ref real-time PCR) 
9 (1.4%) 2/8 (25%) All had parasitemia <200 p/µL  
Median: 1.1, IQR: 0.47 – 20.6  p/µL 
    
*by qPCR    
Discrepancy n Microscopy 
positive 
AL treatment IPTp-SP Any treatment 
False positive RDT 
 (ref real-time PCR) 
20 (3.2%) 2/20 (10%) 4 had received AL in last 14 days (20%) 
4 had received AL in last 28 days (20%) 
6 reported being under treatment with AL 
4 had received SP in last 14 days (20%) 
4 had received SP in last 28 days (20%) 
8 had received AL or SP in last 14 days (40%) 
8 had received AL or SP in last 28 days (40%) 
11 reported or received AL, SP or quinine in last 14 days (55%) 
      
      
RDT positive AL given Reasons non-adherence CHW AL course completed Reasons non-adherence full AL course 
n = 307 239/302 (79.1%) 4/46 no AL available 
53/68 already under treatment (77.9%) 
195/202 (96.5%) 3/7 medicine made woman feel ill 
1/7 forgot to take medicine 
1/7 was already under treatment with AL 
    2/7 unknown 
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